🇪🇺 Nuwiq in European Union

EMA authorised Nuwiq on 22 July 2014

Marketing authorisation

EMA — authorised 22 July 2014

  • Application: EMEA/H/C/002813
  • Marketing authorisation holder: Octapharma AB
  • Local brand name: Nuwiq
  • Indication: Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Nuwiq can be used for all age groups.
  • Status: approved

Read official source →

Nuwiq in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Other approved in European Union

Frequently asked questions

Is Nuwiq approved in European Union?

Yes. EMA authorised it on 22 July 2014.

Who is the marketing authorisation holder for Nuwiq in European Union?

Octapharma AB holds the EU marketing authorisation.